Cargando…
Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
BACKGROUND: Paraquat (PQ) poisoning is a widespread occurrence, especially in underdeveloped areas. The treatment of PQ poisoning has always been difficult, and there is currently no definite effective treatment. Continuous venovenous hemofiltration (CVVH) treatment for PQ poisoning has been widely...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440140/ https://www.ncbi.nlm.nih.gov/pubmed/28514303 http://dx.doi.org/10.1097/MD.0000000000006875 |
_version_ | 1783238020560846848 |
---|---|
author | Lin, Guodong Long, Jianhai Luo, Yuan Wang, Yongan Zewu, Qiu |
author_facet | Lin, Guodong Long, Jianhai Luo, Yuan Wang, Yongan Zewu, Qiu |
author_sort | Lin, Guodong |
collection | PubMed |
description | BACKGROUND: Paraquat (PQ) poisoning is a widespread occurrence, especially in underdeveloped areas. The treatment of PQ poisoning has always been difficult, and there is currently no definite effective treatment. Continuous venovenous hemofiltration (CVVH) treatment for PQ poisoning has been widely used in clinical practice; however, its effect remains uncertain. Accordingly, the purpose of this meta-analysis was to evaluate the efficacy of CVVH in the treatment of PQ poisoning. METHODS: We searched for relevant trials using PubMed, Embase, the Cochrane Library, and 3 Chinese databases, the Chinese BioMedical Literature Database, National Knowledge Infrastructure Database, and Wanfang Database. We included all qualified randomized controlled trials (RCTs) of CVVH treatment for patients with PQ poisoning. The primary outcome was mortality, while the secondary outcomes included the survival time and constituent ratios of death due to respiratory failure and circulatory failure. RESULTS: Three RCTs involving 290 patients were included. The mortality rates of the intervention and control groups were 57.9% and 61.0%, respectively. Pooled analysis demonstrated no significant difference in mortality between the CVVH treatment and control groups (risk ratio [RR] 0.94, 95% confidence interval [CI]: 0.78–1.15, P = .56), with a low level of heterogeneity (X(2) = 1.75, I(2) = 0%). However, the CVVH group was associated with a longer survival time compared to the control group (weighted mean difference 1.73, 95% CI: 0.56–2.90, P = .004). Respiratory failure as the cause of death was more common in the CVVH group, as compared with the control group (RR 1.66, 95% CI: 1.24–2.23, P = .0008), whereas patients in the control group were more likely to die from circulatory failure than in the CVVH group (RR 0.56, 95% CI: 0.40–0.81, P = .002). CONCLUSION: Although CVVH treatment might not noticeably reduce mortality for patients with PQ poisoning, it can prolong the survival time of the patients and improve the stability of the circulatory system, thereby enabling further treatment. |
format | Online Article Text |
id | pubmed-5440140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-54401402017-05-25 Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials Lin, Guodong Long, Jianhai Luo, Yuan Wang, Yongan Zewu, Qiu Medicine (Baltimore) 3900 BACKGROUND: Paraquat (PQ) poisoning is a widespread occurrence, especially in underdeveloped areas. The treatment of PQ poisoning has always been difficult, and there is currently no definite effective treatment. Continuous venovenous hemofiltration (CVVH) treatment for PQ poisoning has been widely used in clinical practice; however, its effect remains uncertain. Accordingly, the purpose of this meta-analysis was to evaluate the efficacy of CVVH in the treatment of PQ poisoning. METHODS: We searched for relevant trials using PubMed, Embase, the Cochrane Library, and 3 Chinese databases, the Chinese BioMedical Literature Database, National Knowledge Infrastructure Database, and Wanfang Database. We included all qualified randomized controlled trials (RCTs) of CVVH treatment for patients with PQ poisoning. The primary outcome was mortality, while the secondary outcomes included the survival time and constituent ratios of death due to respiratory failure and circulatory failure. RESULTS: Three RCTs involving 290 patients were included. The mortality rates of the intervention and control groups were 57.9% and 61.0%, respectively. Pooled analysis demonstrated no significant difference in mortality between the CVVH treatment and control groups (risk ratio [RR] 0.94, 95% confidence interval [CI]: 0.78–1.15, P = .56), with a low level of heterogeneity (X(2) = 1.75, I(2) = 0%). However, the CVVH group was associated with a longer survival time compared to the control group (weighted mean difference 1.73, 95% CI: 0.56–2.90, P = .004). Respiratory failure as the cause of death was more common in the CVVH group, as compared with the control group (RR 1.66, 95% CI: 1.24–2.23, P = .0008), whereas patients in the control group were more likely to die from circulatory failure than in the CVVH group (RR 0.56, 95% CI: 0.40–0.81, P = .002). CONCLUSION: Although CVVH treatment might not noticeably reduce mortality for patients with PQ poisoning, it can prolong the survival time of the patients and improve the stability of the circulatory system, thereby enabling further treatment. Wolters Kluwer Health 2017-05-19 /pmc/articles/PMC5440140/ /pubmed/28514303 http://dx.doi.org/10.1097/MD.0000000000006875 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0 |
spellingShingle | 3900 Lin, Guodong Long, Jianhai Luo, Yuan Wang, Yongan Zewu, Qiu Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials |
title | Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials |
title_full | Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials |
title_fullStr | Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials |
title_full_unstemmed | Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials |
title_short | Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials |
title_sort | continuous venovenous hemofiltration in the management of paraquat poisoning: a meta-analysis of randomized controlled trials |
topic | 3900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440140/ https://www.ncbi.nlm.nih.gov/pubmed/28514303 http://dx.doi.org/10.1097/MD.0000000000006875 |
work_keys_str_mv | AT linguodong continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials AT longjianhai continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials AT luoyuan continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials AT wangyongan continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials AT zewuqiu continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials |